Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions11Disclosure: Soleja: none; Rimawi: Research Grant (GlaxoSmithKline).

Approximately 15%-20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancers are more aggressive, have a propensity for central nervous system (CNS) metastasis, and, historically, carry a poor prognosis. However, with further understanding of HER signaling and development of targeted HER2 therapies, patient outcomes have improved dramatically. Despite significant improvement in treatment outcomes, treatment resistance remains a major clinical problem in metastatic HER2 breast cancer.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research